Disposal

Genus PLC
15 January 2008


15 January 2008

                                   Genus plc
                           ('Genus' or 'the Company')

               Animalcare Disposal and Notice of Interim Results

Animalcare Disposal

Genus, a world leading animal genetics company, is pleased to announce the
completion of the disposal of its non-core veterinary pharmaceutical business,
Animalcare Limited ('Animalcare'), to Ritchey plc ('Ritchey') for a total cash
consideration of £14m, including a deferred element of £0.6m.

The agreement to dispose of Animalcare was announced on 27 November, subject to
Ritchey raising funds upon its admission to the AIM market. Ritchey was today
admitted to trading on AIM.

This sale concludes Genus' programme of non-core business disposals, following
the sales of SyAqua Mexico, the Company's remaining shrimp business, and HTSPE,
the Company's non-core development consulting business, in the first half of the
current financial year.

Notice of Interim Results

Genus will announce its interim results for the six months ended 31 December
2007 on Tuesday 26 February 2008.

For further information, please contact:

Genus plc                                                     Tel: [phone]
Richard Wood, Chief Executive
Martin Boden, Finance Director

Landsbanki Securities (UK) Limited                            Tel: [phone]
Financial Adviser & Joint Broker
Shaun Dobson

Buchanan Communications                                       Tel: [phone]
Charles Ryland / Suzanne Brocks



About Genus

Genus sells added value products for livestock farming and food producers by
creating advances to animal breeding through biotechnology.  Its non-Genetically
Modified Organism (GMO) technology is applicable across all livestock species
but is only commercialised by Genus in the bovine and porcine farming sectors.

Genus' worldwide sales are made in seventy countries under the trade marks 'ABS'
(dairy and beef cattle) and 'PIC' (pigs) and comprise semen and breeding animals
with superior genetics to those animals currently in production.  Customers use
Genus genetics in their herds to produce offspring with greater production
efficiency, milk and meat output and quality. These offspring are used to supply
the global dairy and meat supply chain.

Genus' competitive edge has been created from the ownership and control of
proprietary lines of breeding animals, the biotechnology used to improve them
and the Group's global production and distribution network.

Headquartered in Basingstoke, England, Genus companies operate in 30 countries
on six continents, with research laboratories located in Madison, USA.




                      This information is provided by RNS
            The company news service from the London Stock Exchange